N/A N=62 Vitamin D Supplements for HIV-positive Patients on cART
HIV-associated Co-morbidities
Primary: 25(OH)D Levels — 13; 20 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=286 Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness
Heart Failure · Pulmonary Disease · Cancer
Primary: Caregiver Anxiety — 6.9; 7.3; 5.9; 5.4 units on a scale — p=<0.511
Phase 2 N=24 Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response
Phase 1 N=12 Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin
Pre-diabetes
Primary: Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites — 105.8; 132.7; 162.3; 291.3 nM*hr — p=0.05
Phase 3 N=302 EXTEND (Eltrombopag Extended Dosing Study)
Purpura, Thrombocytopaenic, Idiopathic
Primary: Overall Summary of On-Therapy Adverse Events (Safety Population) — 277; 96; 133; 41 Participants
Phase 2 N=56 Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage
Subarachnoid Hemorrhage · Vasospasm
Primary: Change in Oxygen Delivery in Vulnerable Brain Regions — 3.7; 4.3 ml/100g/min — p=0.001
N/A N=226 The Resource Information Program for Parents on Lifestyle and Education
Pediatric Obesity
Primary: Feasibility (Parents' Interest in the SBIRT.) — 84.3; NA; NA; NA percentage of parents
Phase 3 N=312 Safety and Efficacy of Cariprazine for Mania
Bipolar Disorder · Mania
Primary: Change From Baseline in the Young Mania Rating Scale (YMRS) Total Score at Week 3 — -15.3; -19.6 score on a scale — p=0.0004
Phase 1 N=149 First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Primary: Number of Subjects With Any Dose Limiting Toxicity (DLT) — 1; 3; 2 subjects
N/A N=309 A Comparison of Inhalation vs. Intravenous Induction
Hypothermia
Primary: Measurement of Core Temperature — 36.42; 36.44; 35.96; 36.35 degree C
N/A N=96 Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Vascular Endothelial Growth Factor Overexpression
Primary: VEGF Protein and mRNA Levels — 1395; 1069; 1666 pg/ml — p=<0.001
N/A N=21 Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use
Obstructive Sleep Apnea · Central Sleep Apnea (Diagnosis) · Chronic Opioid Use
Primary: Apnea Hypopnea Index (AHI) — 2.5; 16.3 events/hour
Phase 4 N=87 Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study
Orthostatic; Hypotension, Neurogenic
Primary: Change in Orthostatic BP Drop — 11.1; 13.6; 8.9; 7.5 mmHg
N/A N=71 Effect of IV Lidocaine Infusions on Pain
Pain
Primary: Present Pain Intensity — 6.25; 5.64; 4.92; 4.18 Units on a scale
N/A N=22 Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS
Myopathy · HMG COA Reductase Inhibitor Adverse Reaction · Hypercholesterolemia
Primary: Phosphocreatine Recovery — -18.9; 7.7 percentage change from baseline